| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | AZD-2281 | FIMM | pan-cancer | AAC | -0.022 | 0.9 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.006 | 0.9 |